Ingelfinger Summary Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin analogues that promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and obesity
Understanding how each works helps clarify whether interactions between them are likely
Efficacy and safety of the ghrelin-O-acyltransferase inhibitor BI 1356225 in overweight/obesity: Data from two Phase I, randomised, placebo-controlled studies
Compared to the inhibitors of Gln uptake, GLS inhibitors, such as C968 [152], bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide (BPTES) [153], and CB-839 (telaglenastat) [154], have been more translationally advanced drugs
About this article Cite this article Kunutsor, S.K., Seidu, S
Evaluation of some biochemical changes in diabetic patients